Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
This protein carries a polyhistidine tag at the C-terminus.
The protein has a calculated MW of 35.0 kDa. The protein migrates as 50-60 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
FITC
Excitation source: 488 nm spectral line, argon-ion laser
Excitation Wavelength: 488 nm
Emission Wavelength: 535 nm
>95% as determined by SDS-PAGE.
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally trehalose is added as protectant before lyophilization.
Contact us for customized product form or formulation.
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please protect from light and avoid repeated freeze-thaw cycles.
This product is stable after storage at:
FITC-Labeled Human IL-3 R alpha, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%.
Please contact us via TechSupport@acrobiosystems.com if you have any question on this product.
Explore our catalog of therapeutic antibody solutions to find the right products for you! We are dedicated to delivering solutions designed to help you drive innovation and push the boundaries of what therapeutic antibodies can be.
We offer a wide range of cell and gene therapy solutions starting from discovery to the clinic. Explore our wide range of proteins, antibodies, kits, and other assays to accelerate the development of your cell and gene therapy.
Organoid Toolbox is a collection of organoid solutions including ready-to-use organoids, organoid differentiation kits, and a variety of services to accelerate the progress of your drug development project.
ACROBiosystems developed a series of GMP grade cytokines under the GMP grade quality management system. Those products are all suitable for T/NK cell generation, activation, and proliferation in cell therapy research.
50+ targets designed for CAR detection, including PE/FITC/biotin labeled proteins. The key reagents for CD19 and BCMA were FDA DMF filed which can support your IND, NDA and BLA process.
GMP grade cytokines, reagents for cell activation, gene edition, DNA/RNA removal, etc. Particularly focus on product design, quality control and solution-based support to link each phase of your cell and gene therapy journey.
Full length multi-pass TPs with stabilized structure and high bioactivity for immunization, antibody screening, cell based assay and CAR detection, including hot CD20, Claudin 18.2, CD133, GPRC5D,CCR8, CCR5, etc.
A series of immune checkpoints including classic co-inhibitory and co-stimulatory receptors. The comprehensive catalog contains 100+ targets with various species and tags, and the high-quality proteins are in good batch-to-batch consistency.
To meet the needs of ADCs development, ACROBiosystems can provide: A variety of high-quality target proteins; MMPs/Cathepsin/uPA for cleavable linker; Anti-payload antibodies & anti-idiotypic antibodies for immunogenicity and PK analysis; SPR/BLI analytical and ADA development service.
Comprehensive collection of Fc receptor proteins, including their common variants, which can help expedite your antibody development.
Comprehensive cytokine targets including interleukins, growth factors, chemokines, TNFs, etc. are expressed by HEK293 to ensure their natural structure. Their high purity is verified by SDS-PAGE/HPLC/SEC-MALS and high bioactivity is verified by ELISA/SPR/BLI.
Aneuro provides comprehensive tools for neuroscience research, including neuroscience proteins, pre-formed fibrils (PFFs), neural antibodies, neural factors, and more—aiming to accelerate disease modeling, drug screening, and neural mechanism studies.
English Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
---|---|---|---|---|---|---|---|---|---|---|
Tagraxofusp | SL-401; DTIL-3; DT388 IL3 | Approved | Texas A&M University Development Foundation | Elzonris | United States | Blastic Plasmacytoid Dendritic Cell Neoplasm | Stemline Therapeutics Inc | 2018-12-21 | Leukemia; Myelodysplastic Syndromes; Leukemia, Myelomonocytic, Chronic; Blastic Plasmacytoid Dendritic Cell Neoplasm; Multiple Myeloma; Primary Myelofibrosis; Lymphoma; Leukemia, Myeloid, Acute | Details |
English Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
Talacotuzumab | CSL-362; JNJ-473; CSL-362-AML; JNJ-56022473; IL-13 MAb-CSL | Phase 2 Clinical | Csl Ltd | Myelodysplastic Syndromes; Leukemia, Myeloid, Acute | Details |
Vibecotamab | XmAb-14045 | Phase 2 Clinical | Xencor Inc | Leukemia, Myeloid; Myelodysplastic Syndromes; Blastic Plasmacytoid Dendritic Cell Neoplasm; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Myeloid, Acute | Details |
Pivekimab sunirine | IMGN-632 | Phase 2 Clinical | Immunogen Inc | Leukemia; Myelodysplastic Syndromes; Myeloproliferative Disorders; Blastic Plasmacytoid Dendritic Cell Neoplasm; Leukemia, Myeloid, Acute; Myelodysplastic-Myeloproliferative Diseases | Details |
CD123 CAR-T cell therapy(Chongqing Precision Biotechnology) | Phase 2 Clinical | Chongqing Precision Biotechnology Co Ltd | Leukemia; Leukemia, Myeloid; Blastic Plasmacytoid Dendritic Cell Neoplasm; Leukemia, Myeloid, Acute | Details | |
Anti-CD123 CAR T-cell therapy (Southwest Hospital) | Phase 2 Clinical | The Southwest Hospital of AMU | Leukemia, Myeloid | Details | |
CAR-T Cells Targeting CD33/CD123 therapy(Essen Biotech) | BAH244; BAH-244 | Phase 2 Clinical | Essen Biotech | Leukemia, Myeloid, Acute | Details |
AZD-9829 | AZD9829; AZD-9829 | Phase 2 Clinical | Astrazeneca Plc | Hematologic Neoplasms; Hematologic Diseases; Myelodysplastic Syndromes; Leukemia, Myeloid, Acute | Details |
Anti Tim-3/CD123 CAR-T Cell Therapy(Xuzhou Medical University) | Phase 2 Clinical | Xuzhou Medical University (Xzmu), The Affiliated Hospital Of Xuzhou Medical University | Leukemia, Myeloid, Acute | Details | |
MP0533 | MP0533 | Phase 2 Clinical | Molecular Partners Ag | Leukemia, Myeloid, Acute | Details |
APVO-436 | APVO-436; APVO436 | Phase 2 Clinical | Aptevo | Myelodysplastic Syndromes; Leukemia, Myeloid, Acute | Details |
SAR-443579 | SAR-443579; SAR443579; SAR579; IPH6101; IPH-6101 | Phase 2 Clinical | Sanofi | Hematologic Diseases; Myelodysplastic Syndromes; Blastic Plasmacytoid Dendritic Cell Neoplasm; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, B-Cell; Leukemia, Myeloid, Acute | Details |
Anti-CD123 CAR T-cell therapy (University of Pennsylvania/Novartis) | JEZ-567 | Phase 1 Clinical | Novartis Pharma Ag, University Of Pennsylvania | Leukemia, Myeloid, Acute | Details |
Flotetuzumab | S-80880; MGD-006; RES-234 | Phase 1 Clinical | Macrogenics Inc | Hematologic Neoplasms; Leukemia; Leukemia, Myelogenous, Chronic; Leukemia, Hairy Cell; Mastocytosis, Systemic; Hodgkin Disease; Blastic Plasmacytoid Dendritic Cell Neoplasm; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Neoplasms, Plasma Cell; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Myeloid, Acute; Leukemia, Biphenotypic, Acute | Details |
UCART-123 | UCART-123; UCART-123v1.2 | Phase 1 Clinical | Cellectis Sa | Blastic Plasmacytoid Dendritic Cell Neoplasm; Leukemia, Myeloid, Acute | Details |
JNJ-63709178 | JNJ-9178; CNTO-9958; JNJ-63709178 | Phase 1 Clinical | Johnson & Johnson Innovative Medicine, Genmab A/S | Leukemia, Myeloid, Acute | Details |
Anti-CD123 CAR T cell therapy (Shanghai GeneChem) | Phase 1 Clinical | Shanghai Genechem Co Ltd | Leukemia, Myeloid, Acute | Details | |
IM-23 (Beijing Immunochina Medical Science and Technology) | IM-23; IM-23 CAR-T | Phase 1 Clinical | Beijing Immunochina Medical Science & Technology Co Ltd | Leukemia, Myeloid, Acute | Details |
Anti-CD123 CAR T-cell therapy (Nanjing Legend Biotech) | Phase 1 Clinical | Nanjing Legend Biotechnology Co Ltd | Leukemia, Myeloid, Acute | Details | |
MB-102 (Mustang Bio) | MB-102 | Phase 1 Clinical | Mustang Bio Inc, City Of Hope National Medical Center | Neoplasm, Residual; Blastic Plasmacytoid Dendritic Cell Neoplasm; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Myeloid, Acute; Leukemia, Biphenotypic, Acute | Details |
UniCAR-T-CD-123 | UniCAR-T-CD123; AVC-101 | Phase 1 Clinical | AvenCell Therapeutics Inc, AvenCell Europe GmbH | Leukemia, Myeloid, Acute | Details |
ACLX-002 | ACLX-002 | Phase 1 Clinical | Arcellx Inc | Myelodysplastic Syndromes; Leukemia, Myeloid, Acute | Details |
MGD-024 | MGD-024 | Phase 1 Clinical | Macrogenics Inc | Leukemia, Myelogenous, Chronic; Leukemia, Hairy Cell; Hodgkin Disease; Myelodysplastic Syndromes; Neoplasms; Blastic Plasmacytoid Dendritic Cell Neoplasm; Leukemia, B-Cell; Leukemia, Myeloid, Acute | Details |
AFM-28 | AFM-28 | Phase 1 Clinical | Affimed | Leukemia, Promyelocytic, Acute; Neoplasms; Leukemia, Myeloid, Acute | Details |
VIP943 | BAY-943; VIP-943 | Phase 1 Clinical | Bayer AG | Myelodysplastic Syndromes; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Myeloid, Acute | Details |
Autologous CAR123 T lymphocytes cell tharapy(Institute of Hematology and Blood Transfusion, Czech Republic) | Phase 1 Clinical | Institute of Hematology and Blood Transfusion, Czech Republic | Myelodysplastic Syndromes; Blastic Plasmacytoid Dendritic Cell Neoplasm; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Myeloid, Acute | Details | |
Anti-CD123 CAR NK cells therapy(Chongqing Precision Biotechnology) | Phase 1 Clinical | Chongqing Precision Biotechnology Co Ltd | Neoplasms, Plasma Cell; Leukemia, Myeloid, Acute | Details | |
CD123 CAR-NK cell therapy(Beijing JD Biotech) | JD123; JD-123 | Phase 1 Clinical | Beijing JD Biotech Co Ltd | Leukemia, Myeloid, Acute | Details |
Universal CAR-T Cells therapy(Shenzhen Geno-Immune Medical Institute) | Phase 1 Clinical | Shenzhen Geno-Immune Medical Institute | Leukemia, Myeloid, Acute | Details | |
AVC-201 | AVC-201; Allo-RevCAR01-T-CD123 | Phase 1 Clinical | AvenCell Europe GmbH | Leukemia, Myeloid, Acute | Details |
CD123-CAR T cells(St Jude Children's Research Hospital) | Phase 1 Clinical | St. Jude Children'S Research Hospital | Myelodysplastic Syndromes; Blastic Plasmacytoid Dendritic Cell Neoplasm; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | Details | |
LAVA-1266 | LAVA-1266; LAVA1266 | Phase 1 Clinical | Lava Therapeutics NV | Hematologic Neoplasms; Leukemia, Myeloid, Acute | Details |
Allogenic CD123-CAR-NK Cells therapy(JD Biotech) | JD023 | Phase 1 Clinical | Beijing JD Biotech Co Ltd, Chinese Academy Of Military Medical Sciences | Leukemia, Myeloid, Acute | Details |
BYON-4413 | BYON-4413 | Phase 1 Clinical | Byondis Bv | Hematologic Neoplasms; Leukemia, Myeloid, Acute | Details |
GR-1901 | GR1901; GR-1901 | Phase 1 Clinical | Chongqing Zhixiang Jintai Biopharmaceutical Co Ltd, Genrix (Shanghai) Biopharmaceutical Co Ltd | Leukemia, Myeloid, Acute | Details |
SQZ-622(Novartis Pharma) | SQZ-622 | Phase 1 Clinical | Novartis Pharma Ag | Leukemia, Myeloid, Acute | Details |
UniCAR02-T | UniCAR02-T | Phase 1 Clinical | Cellex Patient Treatment Gmbh | Kidney Neoplasms; Prostatic Neoplasms; Breast Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
IL3 CAR T-cell therapy (Yake Biotechnology) | Phase 1 Clinical | Zhejiang University | Leukemia, Myeloid, Acute | Details | |
Anti-CD123 chimeric antigen receptor T cell therapy (Yake Biotechnology) | Clinical | Shanghai YaKe Biotechnology Co Ltd | Leukemia, Myeloid, Acute | Details |
This web search service is supported by Google Inc.